26 results about "Low density lipoprotein cholesterol level" patented technology

The invention relates to an application of an Sdccag3 gene in preparation of a weight-reducing medicine for regulating glucose and lipid metabolism. The Sdccag3 gene is used as an action target to be applied to preparation or screening of the weight-reducing medicine for regulating glucose and lipid metabolism, and the nucleotide sequence of the Sdccag3 gene is as shown in SEQ ID No. 1. According to the application disclosed by the invention, the specific overexpressed Sdccag3 in adipose tissues in a mouse body can obviously inhibit the increase of the blood fat level, and the overexpressed Sdccag3 can also obviously improve the poor glucose tolerance, improve the insulin sensitivity, reduce the levels of serum triglyceride, cholesterol and low-density lipoprotein cholesterol of an obese mouse, improve the poor glucose tolerance and improve the insulin sensitivity. The insulin sensitivity is improved, obesity-related glycolipid metabolism is effectively regulated and controlled, the effect of reducing blood lipid and blood sugar is achieved, and the compound can be used for preparing weight-losing drugs for reducing blood lipid and blood sugar.

The invention discloses an application of an intestinal strain in preparation of a cholesterol-lowering product, and belongs to the technical field of microbial medicines. The intestinal bacterial strain is Oscillibacter ruminant, the viable bacteria concentration of the intestinal bacterial strain is controlled to be (4.8-5.2) * 10 < 9 > CFU / mL, the intestinal bacterial strain can be prepared into bacterial liquid, freeze-dried powder, capsules or tablets and other dosage forms, and pharmaceutically acceptable auxiliary materials such as lactose and microcrystalline cellulose can be added. According to the cholesterol-lowering product, the total cholesterol, triglyceride and low-density lipoprotein cholesterol level of an object can be remarkably reduced under the action of peste des petits ruminants, and meanwhile, the high-density lipoprotein cholesterol level is increased; in addition, abnormal blood glucose induced by high-fat diet can be improved, arterial lipid accumulation is reduced, and the plaque area proportion of atherosclerotic lesions is improved.

The invention discloses compound probiotics for reducing blood fat and regulating constipation and application of the compound probiotics in resistant starch fermented milk, and belongs to the technical field of functional food. The compound bacterium is prepared from bifidobacterium animalis IU100 and lactobacillus paracasei ZYhyy-004, and the compound bacterium has a synergistic interaction effect, and the compound bacterium can be used for preparing the compound bacterium. The resistant starch is used for preparing the resistant starch fermented milk, the levels of serum total cholesterol, triglyceride and low-density lipoprotein cholesterol can be remarkably reduced, the content of high-density lipoprotein cholesterol is increased, meanwhile, the intestinal tract propulsion rate is increased, and functional constipation is improved. The fermented milk realizes dual effects of reducing blood fat and improving intestinal functions by regulating intestinal flora balance, promoting proliferation of beneficial bacteria and inhibiting growth of pathogenic bacteria. The invention provides a new way for developing multifunctional probiotic foods.

The invention discloses compound safflower tea capable of reducing blood lipid. The compound safflower tea consists of the following components: 0.19 to 0.21 g of safflower, 0.195 to 2.050 g of American ginseng, 0.90 to 1.10 g of green tea, 1.10 to 1.20 g of hawthorn and 1.35 to 1.45 g of lotus leaf. According to the present invention, the C57BL / 6J mouse is subjected to the lipid-lowering experiment by using the safflower as the main material and using the American ginseng, the green tea, the hawthorn and the lotus leaf as the auxiliary materials, and the result shows that the safflower lipid-lowering tea can significantly reduce the levels of serum total cholesterol (TC), triglyceride (TG) and low density lipoprotein cholesterol (LDL-C), can improve the liver fatty degeneration and the inflammatory reaction, and can alleviate the intestinal injury caused by the high fat diet; animal behavior experiments including Y maze, open field experiments and new object recognition experiments are used to verify that the safflower lipid-lowering tea has an improvement effect on mouse cognitive impairment caused by dyslipidemia.

The application discloses a Hypsizygus marmoreus extract and a preparation method and application thereof. The extract is prepared from the Hypsizygus marmoreus through a method combining water extraction, alcohol precipitation, macroporous adsorption resin and silica gel column chromatography, UPLC-ESI-MS / MS analysis identifies 830 compounds, and 26 main compound components with a relative content of more than 0.2%; network pharmacology analysis obtains 40 active compounds and 23 T2MD related core target points. The extract can significantly reduce fasting blood glucose and postprandial blood glucose, can significantly reduce serum total cholesterol, triglyceride and low-density lipoprotein cholesterol levels, can improve fatty liver level, can significantly reduce serum inflammatory factors IL-6, TNF-alpha and CRP levels, can significantly increase GLP-1 and serum insulin levels, and can improve intestinal flora alpha diversity, improve beta diversity structure and restore the abundance of beneficial bacteria. The Hypsizygus marmoreus extract has multi-target and multi-metabolic regulation functions, can be used for developing a blood glucose and blood lipid reducing medicine or health food, and has high safety and definite effect.

The invention provides a soda water beverage added with nattokinase and a preparation method and application thereof, the soda water beverage added with nattokinase has a pH value of 7.8-8.2 and a carbonation degree of 0.8-1.2 g / L, and contains nattokinase, and the activity of the nattokinase is greater than or equal to 10,000 FU / L. The soda water beverage added with the nattokinase is applied to preparation of products for regulating PCSK9 activity, reducing the low density lipoprotein cholesterol LDL-C level in blood or preventing / assisting in managing obesity and related metabolic syndromes. The product is a beverage, a health food or a dietary supplement. The nattokinase can be used for specifically hydrolyzing the Ser153-Gly154 site of the PCSK9 protein, and the Ser153-Gly154 site of the PCSK9 protein can be specifically hydrolyzed. According to the beverage, the activity of nattokinase is protected by optimizing pH and a carbonation system, the intestinal absorption rate of the nattokinase is improved, and the function of PCSK9 is inhibited in a targeted manner so as to regulate blood lipid metabolism. Compared with an existing oral enzyme preparation, the oral enzyme preparation has high efficiency, stability and consumption convenience, and an innovative diet intervention scheme is provided for obesity and related metabolic diseases.

The invention discloses application of intestinal flora metabolite reuterin in preparation of a medicine for relieving or treating atherosclerosis, and relates to the technical field of medicine. The reuterin can reduce the blood sugar level, the total cholesterol level and the low-density lipoprotein cholesterol level, reduce liver lipid deposition, improve liver fatty degeneration, promote growth of beneficial bacteria, inhibit proliferation of potential harmful bacteria and inhibit cell penetration and uptake of low-density lipoprotein in endothelial cells. According to the application, the fact that the reuterin can be used for relieving or treating the atherosclerosis is disclosed for the first time, a new direction is provided for treating the atherosclerosis, and experiments show that the reuterin does not cause adverse effects on liver and kidney functions of mice after being used for a long time, and shows that the reuterin has good biological safety.

The application discloses a compound probiotic for lowering blood lipid and regulating constipation and application of the compound probiotic in resistant starch fermented milk, and belongs to the technical field of functional food. The compound probiotic is composed of Bifidobacterium animalis IU100 and Lacticaseibacillus paracasei ZYhyy-004, and has a synergistic effect. The compound probiotic is used for preparing resistant starch fermented milk, can significantly reduce the levels of serum total cholesterol, triglyceride and low-density lipoprotein cholesterol, increase the content of high-density lipoprotein cholesterol, enhance the intestinal propulsion rate and improve functional constipation. The fermented milk can regulate intestinal flora balance, promote the proliferation of beneficial bacteria and inhibit the growth of pathogenic bacteria, and realizes the dual effects of lowering blood lipid and improving intestinal function. The application provides a new way for developing multifunctional probiotic food.

The invention discloses goose plasma protein source oligopeptide capable of improving liver lipid metabolism disorder and application of the goose plasma protein source oligopeptide, and relates to the technical field of biology. The goose plasma protein source oligopeptide capable of improving liver lipid metabolism disorder is obtained through screening, and the amino acid sequence is GDWIVK. Animal experiments prove that the goose plasma protein source oligopeptide can effectively reduce the levels of triglyceride, total cholesterol and low-density lipoprotein cholesterol in serum and liver affected by high fat diet, increase the content of high-density lipoprotein cholesterol, reduce liver lipid deposition and improve pathological injury of the liver. Meanwhile, the structure and diversity of intestinal flora can be adjusted, the abundance of beneficial bacteria and the content of short-chain fatty acid in excrement are increased, the reaction of colitis is relieved, and the synergistic adjustment effect is achieved through an intestinal tract-liver axis.

The invention discloses a medicine for treating atherosclerosis caused by high fat diet, and belongs to the technical field of cardiovascular disease treatment. According to the pharmaceutical composition, siRNA (small interfering Ribonucleic Acid) capable of inhibiting expression of LncRNA-ENST00000564510.1 in a targeted manner is used as a core active component, and is combined with a delivery system for use. Animal experiments prove that the siRNA injection medicine can remarkably reduce the aortic plaque area of an atherosclerosis model mouse and effectively improve the levels of serum total cholesterol, triglyceride and low-density lipoprotein cholesterol. Meanwhile, the medicine can remarkably inhibit secretion of vascular endothelial cell inflammatory factors induced by ox-LDL, and the cell activity is improved. Therefore, the invention provides a novel therapeutic drug based on lncRNA targeted regulation, and the novel therapeutic drug has an excellent anti-atherosclerosis effect.

The present application relates to the technical field of biotechnology, and discloses a plant Lactobacillus plantarum XKFY202518 and application of the plant Lactobacillus plantarum XKFY202518 in preparation of a type 2 diabetes auxiliary preparation for improving insulin resistance and regulating blood lipid, the plant Lactobacillus plantarum XKFY202518 has a preservation number of CGMCC No.34745 in China General Microbiological Culture Collection Center, and a preservation date of June 3, 2025.The plant Lactobacillus plantarum XKFY202518 separated by the present application can effectively reduce the fasting blood glucose level, insulin level, total cholesterol level, triglyceride level, low-density lipoprotein cholesterol level, alanine aminotransferase level and aspartate aminotransferase level of a diabetic mouse, and increase the high-density lipoprotein cholesterol level of the mouse serum, thereby improving the hyperglycemia and hyperlipidemia symptoms of a type 2 diabetes mouse.

The present invention relates to the field of biomedicine, and particularly to a American ginseng composition for reducing blood lipid and its application. The present invention enzymatically hydrolyzes American ginseng with neutral protease and papain to extract a bioactive short peptide AQFTHWKLH, which can effectively reduce the levels of serum total cholesterol, triglyceride and low-density lipoprotein cholesterol, increase the level of high-density lipoprotein cholesterol, and also has the function of enhancing the antioxidant system. The present invention also relates to a composition containing the short peptide and its application in the preparation of drugs for reducing blood lipid; experiments prove that the composition has a significant blood lipid-lowering effect and has broad application prospects.

The invention provides a diglyceride-containing blood fat reducing composition as well as a preparation method and application thereof, and belongs to the technical field of biological medicines and foods. The composition for reducing blood fat is prepared from 70 to 80 parts of diglyceride oil, 10 to 20 parts of astaxanthin and 5 to 10 parts of chestnut mushroom polysaccharide. The blood fat reducing composition can effectively reduce the level of total cholesterol and triglyceride and adjust the level of high-density lipoprotein cholesterol and low-density lipoprotein cholesterol, and the blood fat reducing effect is remarkable. The diglyceride oil, the astaxanthin and the chestnut mushroom polysaccharide have no incompatibility, are relatively high in safety, and can be used for preparing lipid-lowering drugs or functional foods for assisting in lowering blood lipid so as to prevent or treat dyslipidemia.

The invention belongs to the technical field of microorganisms, and provides enterococcus faecalis FC-1 helpful for reducing blood fat and application of the enterococcus faecalis FC-1, the enterococcus faecalis FC-1 is preserved in the China General Microbiological Culture Collection Center, and the preservation number is CGMCC No.33967. The enterococcus faecalis FC-1 can be used for reducing blood fat. In a model experiment of a golden hamster fed with a high-fat and high-cholesterol feed, the strain shows the capabilities of retarding weight gain and fat deposition, and reducing blood fat and liver lipid level; after intervention, the liver index of the hamster is reduced by 24.74%, the triglyceride level in serum is reduced by 3.93 times, the total cholesterol level is reduced by 2.05 times, the low-density lipoprotein cholesterol level is reduced by 3.02 times, and the triglyceride level, the total cholesterol level and the low-density lipoprotein cholesterol level in the liver are respectively reduced by 34.44%, 58.85% and 40.76%. The strain can be used for preparing medicines and health-care products for losing weight, treating fatty liver and reducing blood fat.

The invention relates to the field of biological medicine, in particular to an American ginseng composition for reducing blood fat and application thereof. The oligopeptide AQFTHWKLH with biological activity is extracted through enzymolysis of American ginseng with neutral protease and papain, and the oligopeptide can effectively reduce the levels of serum total cholesterol, triglyceride and low-density lipoprotein cholesterol and improve the level of high-density lipoprotein cholesterol and also has the function of enhancing an antioxidant system. The invention also relates to a composition containing the oligopeptide and an application of the oligopeptide in preparation of drugs for reducing blood fat. Experiments prove that the composition has a remarkable blood fat reducing effect and has a wide application prospect.

The invention discloses lactobacillus mucus fermentation HF04 with cholesterol lowering capacity and application of the lactobacillus mucus fermentation HF04. The lactobacillus mucus fermentation HF04 is lactobacillus mucus fermentation HF04 and is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC NO.25482. The invention further discloses a preparation method of the lactobacillus mucus fermentation HF04. Probiotic strains with cholesterol removing capacity are screened out according to in-vitro experiments, and strains with good tolerance are obtained through simulated gastric juice and simulated intestinal juice tolerance experiments of the strains. Experiments prove that the lactobacillus mucilaginosus HF04 disclosed by the invention has acid-resistant and cholate-resistant capabilities, and in-vitro and in-vivo experiments show that the lactobacillus mucilaginosus HF04 has cholesterol removal capability; animal experiments show that the strain has the function of remarkably reducing cholesterol, can reduce the level of total cholesterol, triglyceride and low-density lipoprotein cholesterol in serum, and meanwhile, can remarkably reduce the level of liver lipid and relieve liver injury caused by long-term high-fat diet of mice.

The application belongs to the technical field of preoperative management of weight loss surgery, and particularly relates to a preoperative training system for obese patients and application thereof. The application provides a preoperative training system for obese patients, which comprises a physiological system evaluation module, a movement planning module and a nutrition module. The preoperative training system according to the application can significantly reduce the fasting blood glucose level, triglyceride level and low-density lipoprotein cholesterol level of obese patients after metabolic and weight loss surgery, thereby effectively improving the metabolic disorder of the patients, which has important clinical significance for improving the postoperative recovery process of obese patients, improving the quality of life and consolidating the long-term efficacy of weight loss surgery. The preoperative training system according to the application fills the technical gap in the preoperative management of obese patients, provides a non-invasive and efficient auxiliary system, and has a broad clinical application prospect.

The invention provides a krill oil soft capsule as well as a preparation method and application thereof, and belongs to the technical field of development of marine resource health-care food, the krill oil soft capsule is prepared by adopting a specific formula and a specific process, the activity of components in a product can be effectively reserved, all the components have a synergistic effect, and the effect of improving the quality of the product is achieved. The soft capsule provided by the invention can significantly improve atherosclerosis related pathological states, effectively reduce serum total cholesterol, triglyceride and low density lipoprotein cholesterol levels, reduce atherosclerosis indexes, significantly inhibit aortic plaque formation and liver lipid deposition, and maintain stable weight and fat distribution. The product can be used as a health-care food for preventing and assisting in improving atherosclerosis.

The invention belongs to the technical field of medicines and disease treatment, and particularly relates to a traditional Chinese medicine composition for treating atherosclerosis and a preparation method and application thereof. The composition is prepared by taking rhizoma pinellinae praeparata, rhizoma coptidis, pericarpium trichosanthis, radix angelicae sinensis, rhizoma chuanxiong, ground beeltle, radix salviae miltiorrhizae and radix ginseng as raw medicinal materials and adding sucralose and maltodextrin. Wherein berberine and palmatine in coptis chinensis are core active components, and play a role in regulating blood fat, inhibiting inflammation and blocking foam cell formation. Researches show that the particles can significantly reduce the serum total cholesterol, triglyceride and low-density lipoprotein cholesterol levels of model animals, increase the high-density lipoprotein cholesterol level, reduce the aortic plaque area and inhibit RAW264.7 cell foaming, the curative effect is equivalent to that of simvastatin, and a new choice is provided for prevention and treatment of atherosclerosis.

The invention discloses hippophae rhamnoides polysaccharide as well as a preparation method and application thereof. The hippophae rhamnoides polysaccharide has a structure as shown in a formula (I) and is a homogeneous polysaccharide obtained by separating and purifying hippophae rhamnoides fruit residues, the content of arabinofuranose is 66%-72%, the content of galacturonic acid is 7%-11%, and the molecular weight is 2000-3000 Da. The hippophae rhamnoides polysaccharide can significantly reduce triglyceride, total cholesterol and low-density lipoprotein cholesterol levels, reduce lipid droplet accumulation and improve antioxidant enzyme activity, and the action mechanism of the hippophae rhamnoides polysaccharide is related to down-regulation of FAS, ACC and SREBP-1 protein expression and activation of an Nrf2 / HO-1 pathway. According to the invention, high-valued utilization of sea buckthorn pomace resources is realized, and a new candidate substance is provided for developing natural products with lipid-lowering and antioxidant functions.

Disclosed herein are methods for inducing colanic acid production in E. coli by contacting an E. coli bacterium with cephaloridine at a concentration below the minimum inhibitory concentration for growth, wherein ZraS mediates the induction of colanic acid production in the E. coli bacterium. Also disclosed herein are methods for treating age-related metabolic dysfunction, and in particular age-related metabolic dysfunction characterized by elevated insulin and elevated low density lipoprotein (LDL) cholesterol levels relative to high density lipoprotein (HDL) levels.

The present invention relates to methods of decreasing body weight, maintaining body weight, decreasing liver weight, and decreasing levels of triglycerides, total cholesterol, and low-density lipoprotein cholesterol in the blood. The present invention also relates to methods for treating liver disease, e.g., fatty liver disease, in human subjects by administering an activator of sirtuin 6 (SIRT6). Exemplary fatty liver diseases or disorders include, but are not limited to, Metabolic Dysfunction-Associated Steatohepatitis, and hepatic steatosis.

The present disclosure relates to a targeting oligonucleotide for the treatment of PCSK9 related diseases, the targeting oligonucleotide comprising an antisense strand having a sequence as shown in any one of SEQ ID NO: 53-106 or a fragment thereof, or a modified sequence of the sequence or fragment thereof. The targeting oligonucleotide significantly inhibits the expression level of the PCSK9 gene, reduces the level of low-density lipoprotein cholesterol (LDL-C) in blood, and shows a good lipid-lowering effect.

This invention belongs to the field of traditional Chinese medicine preparations, specifically relating to a traditional Chinese medicine composition for weight loss, its preparation method, and its application. The traditional Chinese medicine composition of this invention is made from the following raw materials in parts by weight: 15-25 parts Angelica sinensis, 8-12 parts Astragalus membranaceus, 8-12 parts Citrus reticulata peel, and 8-12 parts Nelumbo nucifera leaf. In this invention, Angelica sinensis is the principal herb, promoting blood circulation and unblocking collaterals; Astragalus membranaceus is the assistant herb, tonifying qi and promoting digestion; Citrus reticulata peel is the adjuvant herb, regulating qi and resolving phlegm; and Nelumbo nucifera leaf is the guiding herb, clearing heat and promoting diuresis. The entire formula works synergistically to resolve phlegm, promote diuresis, strengthen the spleen, and soothe the liver. Animal experiments have shown that the composition of this invention can significantly reduce weight gain, fat accumulation, and liver fat content in obese mice, improve oral glucose tolerance, and reduce serum triglyceride and low-density lipoprotein cholesterol levels. At the same time, it can significantly restore the diversity of intestinal flora α, increase the abundance of beneficial bacteria and reduce the abundance of harmful bacteria, effectively improve the intestinal flora disorder induced by a high-fat diet in mice, and the remodeled intestinal flora can play a role in weight loss. Thus, this invention provides a safe, effective, and palatable new traditional Chinese medicine compound solution for metabolic disorders and intestinal microecological imbalance.

Disclosed herein are methods for inducing colanic acid production in E. coli by contacting an E. coli bacterium with cephaloridine at a concentration below the minimum inhibitory concentration for growth, wherein ZraS mediates the induction of colanic acid production in the E. coli bacterium. Also disclosed herein are methods for treating age-related metabolic dysfunction, and in particular age-related metabolic dysfunction characterized by elevated insulin and elevated low density lipoprotein (LDL) cholesterol levels relative to high density lipoprotein (HDL) levels.